Participants 0 83 5
Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma:
Participants 231 367 5
patients with resected renal cell carcinoma (RCC) at high risk for recurrent disease (TNM stages III and IV resected distant metastases)
Participants 390 523 5
Patients with surgically resected locally advanced (T3-4 or N1-2) or metastatic RCC were randomly assigned to 1 of 4 treatment groups
Participants 1081 1160 5
Forty-one patients were entered in the study and 40 were evaluable for toxicity
